Endo's pipeline updated... The chart of Endo's "Products in Development" was just recently updated. It appears in the R&D section of Endo's website.
Octreotide implant was finally removed from chart per note below the chart. As was Opana ER "crush resistant" formulation after recent FDA approval. BEMA Bup was just added. Urocidin now more prominent/ commands more attention by resulting placement.
-
Per Endo press release...On November 11, 2011,Endo Pharmaceuticals Holdings Inc. (the "Company") decided toterminatethe development of its octreotide implant for the treatment of acromegaly. Thedecision was made after conducting an in-depth review of the Company's research and development activities, including ananalysis of research and development priorities, focus and available resources for current and future projects and the commercial potential for the product.
Cannot downplay Urocidin much longer! Several Endo presentations coming up (see their website for details). Look forward to seeing this updated chart in their PPT presentation (and, Endo speaking more to the status of Urocidin's second phase III clinical trial). Also, look forward to hearing questions about Urocidin from the analysts of major firms south of the border. And, hopefully the market finally starts to recognize the potential of Urocidin and begins to price it into the sp. It is just a matter of time....
Have a good evening, rg